Loading...
OTCMDSNKY
Market cap53bUSD
Dec 20, Last price  
28.15USD
1D
1.33%
1Q
-18.62%
Jan 2017
316.01%
IPO
333.52%
Name

Daiichi Sankyo Co Ltd

Chart & Performance

D1W1MN
OTCM:DSNKY chart
P/E
41.79
P/S
5.24
EPS
105.86
Div Yield, %
125.68%
Shrs. gr., 5y
-0.30%
Rev. gr., 5y
11.49%
Revenues
1.60t
+25.28%
587,830,000,000925,918,000,000929,507,000,000880,120,000,000842,147,000,000952,105,000,000967,365,000,000938,677,000,000997,852,000,0001,118,241,000,000919,372,000,000986,446,000,000955,124,000,000960,195,000,000929,717,000,000981,793,000,000962,516,000,0001,044,892,000,0001,278,478,000,0001,601,688,000,000
Net income
200.73b
+83.84%
48,282,000,00087,693,000,00078,550,000,00097,660,000,000-215,499,000,00041,852,000,00070,121,000,00010,383,000,00066,621,000,00060,943,000,000322,119,000,00082,282,000,00053,466,000,00060,282,000,00093,409,000,000129,074,000,00075,958,000,00066,972,000,000109,188,000,000200,731,000,000
CFO
599.26b
+423.31%
96,703,000,000132,760,000,000106,430,000,00066,667,000,00078,383,000,000130,235,000,000141,139,000,00092,569,000,000129,247,000,00037,304,000,000142,776,000,000174,281,000,000136,234,000,000108,439,000,00092,033,000,000196,601,000,000192,207,000,000139,226,000,000114,514,000,000599,258,000,000
Dividend
Sep 28, 20230.090046 USD/sh
Earnings
Jan 29, 2025

Profile

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
URL
https://www.daiichisankyo.co.jp/
IPO date
Sep 28, 2005
Employees
17,435
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,601,688,000
25.28%
1,278,478,000
22.36%
1,044,892,000
8.56%
Cost of revenue
1,417,488,000
1,176,316,000
971,865,000
Unusual Expense (Income)
NOPBT
184,200,000
102,162,000
73,027,000
NOPBT Margin
11.50%
7.99%
6.99%
Operating Taxes
36,217,000
17,666,000
6,543,000
Tax Rate
19.66%
17.29%
8.96%
NOPAT
147,983,000
84,496,000
66,484,000
Net income
200,731,000
83.84%
109,188,000
63.04%
66,972,000
-11.83%
Dividends
(67,080,000)
(54,616,000)
(51,730,000)
Dividend yield
0.73%
0.59%
1.01%
Proceeds from repurchase of equity
(25,000)
(24,000)
20,391,000
BB yield
0.00%
0.00%
-0.40%
Debt
Debt current
399,000
41,396,000
20,394,000
Long-term debt
185,010,000
140,531,000
182,527,000
Deferred revenue
680,166,000
59,333,000
63,529,000
Other long-term liabilities
212,947,000
359,100,000
256,222,000
Net debt
(610,285,000)
(870,086,000)
(827,371,000)
Cash flow
Cash from operating activities
599,258,000
114,514,000
139,226,000
CAPEX
(88,321,000)
(67,366,000)
(76,682,000)
Cash from investing activities
(282,636,000)
(257,782,000)
212,339,000
Cash from financing activities
(123,564,000)
(89,594,000)
(86,231,000)
FCF
(364,590,000)
(14,852,000)
11,468,000
Balance
Cash
647,180,000
825,126,000
843,845,000
Long term investments
148,514,000
226,887,000
186,447,000
Excess cash
715,609,600
988,089,100
978,047,400
Stockholders' equity
1,723,269,000
2,727,642,000
2,571,080,000
Invested Capital
2,009,661,400
997,815,900
849,126,600
ROIC
9.84%
9.15%
8.17%
ROCE
6.73%
5.11%
3.97%
EV
Common stock shares outstanding
1,918,655
1,918,587
1,918,499
Price
4,777.00
-0.93%
4,822.00
79.93%
2,680.00
-16.90%
Market cap
9,165,414,935
-0.93%
9,251,426,514
79.93%
5,141,577,320
-17.90%
EV
8,555,558,935
9,626,322,514
5,496,931,320
EBITDA
248,417,000
169,951,000
131,272,000
EV/EBITDA
34.44
56.64
41.87
Interest
6,026,000
8,480,000
5,753,000
Interest/NOPBT
3.27%
8.30%
7.88%